Search results for:
nadofaragene firadenovec
nadofaragene firadenovec
Drug Name |
Form |
Strength |
ARHS |
Blue Ridge |
Caldwell |
Chatham |
Johnston |
Lenoir |
Medical Center |
Nash |
Pardee |
Rex |
Rockingham |
Southeastern |
Wayne |
Youth Behavioral Health |
Nadofaragene Firadenovec-vncg |
SUSPENSION, INTRAVESICAL |
3 × 10^11 viral particles/mL (20 mL) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Last updated: Mar. 8, 2024
UNC Health
Caution – Biologic Risk; See below for exposure mitigation strategies
System Formulary Restriction:
Use of nadofaragene firadenovec-vncg intravesical suspension is restricted to outpatient encounters or clinic use only (ie, no inpatient use)
Nadofaragene firadenovec-vncg orders must be signed by a Urology/Oncology Attending Physician